Journal of Clinical Oncology
Articles in this Issue
Phase 1 dose escalation study of CD34 selected CD19 directed CAR T with metabolic programming in relapsed/refractory B-cell lymphoma.
2544 Background: CD19 CAR T cell therapy (CAR-19) has been a breakthrough for relapsed/refractory (R/R) B-cell non-Hodgkin...
Phase II study of NC410 and FOLFIRINOX in combination with nivolumab with or without ipilimumab in patients with treatment-naive metastatic pancreatic cancer.
TPS4260 Background: Pancreatic adenocarcinoma (PDAC) is now the third leading cause of cancer-related death in the United...
AI-based opportunistic risk model to predict pancreatic cancer risk using pre-diagnostic contrast-enhanced CT scans.
e16470 Background: Pancreatic cancer (PC) remains a leading cause of cancer-related mortality. While surgical resection of...
Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
7517 Background: Frontline therapy for patients with multiple myeloma (MM) has mainly consisted of a proteasome inhibitor...
Comparison of anthracycline-containing and anthracycline-free neoadjuvant regimens in HER2-positive breast cancer.
e13021 Background: Concurrent anti-HER2 therapies and chemotherapy improve response rates (43%-55% in prior studies). Howe...
Safety and efficacy of BAL0891 as monotherapy and in combination with paclitaxel: Results from a phase I study in advanced solid tumors.
e15160 Background: BAL0891 is a first-in-class dual threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) inhibito...
A phase II trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC).
TPS4629 Background: Immunotherapy doublet combinations (+/- vascular endothelial growth factor receptor-tyrosine kinase in...
A retrospective study of donafenib with or without TACE as postoperative adjuvant therapy for hepatocellular carcinoma (HCC) patients at high risk of recurrence after radical resection.
e16258 Background: Although hepatectomy offers a potential cure for HCC, postoperative recurrence remains high and adverse...
Impact of <i>NPM1</i> co-mutation on post-transplant outcomes in MRG-mutated AML.
6562 Background: Myelodysplasia-related gene (MRG) mutations are classified as adverse risk per ELN 2022, and allogeneic c...
Multiple myeloma in the United States and India: An international, collaborative study comparing patient characteristics and treatment patterns.
e19506 Background: Multiple myeloma (MM) is one of the most common hematological malignancies globally, and has an array o...
Niraparib and dostarlimab in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with (chemo)radiotherapy (CRT): Results from the phase IB-II TTCC-2022-01 RADIAN trial.
6096 Background: Treatment intensification with antiPD-(L)1 agents given concurrently to definitive CRT in LA-HNSCC have f...
Alrizomadlin (APG-115) alone or in combination with lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs).
10012 Background: Pediatric tumors rarely harbor TP53 mutations but often overexpr...
Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer.
5509 Background: Pts with advanced ovarian cancer (OC) that progresses after platinum-based chemotherapy and subsequent tr...
Insights from initial scoring in the Health Equity Report Card (HERC) pilot in community oncology settings.
11094 Background: The Health Equity Report Card (HERC) is an innovative tool designed to assess and promote equity in canc...
Overall survival after stereotactic radiosurgery for brain metastases in renal cell carcinoma: A contemporary real-world analysis.
e16598 Background: Brain metastases occur in a substantial proportion of patients with renal cell carcinoma (RCC) and are...
Arterial and venous thromboembolic events in <i>ALK</i> - and <i>ROS1</i> -positive non–small cell lung cancer (NSCLC): A multicenter real-world analysis.
e23419 Background: Current risk assessment for cancer-associated thrombosis remain suboptimal in NSCLC, likely due to unac...
Response to venetoclax-containing regimens in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL).
e18528 Background: Patients (pts) with R/R T-ALL/LBL have poor outcomes with limited approved therapies available to them....
Neutrophil counts as a prognostic biomarker following breast cancer surgery: Insights from a Mayo Clinic platform study.
e12691 Background: Breast cancer prognosis is influenced not only by tumor-specific factors but also by systemic inflammat...
Phase I study of BL-M05D1, a novel Claudin18.2-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic Claudin18.2–expressing solid tumors.
3030 Background: BL-M05D1 is a novel Claudin18.2-directed ADC with a potent topoisomerase I inhibitor Ed-04. Results for s...
Impact of facility type on outcomes for elderly patients (≥ 75 years) with Burkitt lymphoma: Real-world data of academic vs community cancer programs.
e19059 Background: Burkitt lymphoma (BL) is an aggressive B-cell malignancy characterized by rapid proliferation. While hi...
A two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study.
6540 Background: Leukemogenesis mirrors hematopoietic differentiation yet proceeds through dysregulated programs. Multipar...
Lung cancer incidence and PM <sub>2.5</sub> : Evaluating the association with varying spatial scales and durations of exposure estimates.
10600 Background: Particulate matter with a diameter of 2.5 µm or less (PM 2.5 ) i...
TALENT: A randomized phase 2 study of talazoparib with or without enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) alterations after progression on abiraterone acetate.
TPS5145 Background: The phase 3 TALAPRO-2 study (NCT03395197) demonstrated superior efficacy with enzalutamide plus talazo...
Management of first recurrence from IDH-wildtype glioblastoma with re-resection or stereotactic radiosurgery: A retrospective, international, multicenter study.
2063 Background: Optimal management of recurrent glioblastoma remains ill-defined. While re-resection is frequently provid...
Long term effects of treatment with dabrafenib (D) and/or trametinib (T) in pediatric patients with MAPK pathway-activated tumors.
10031 Background: Studies have shown the clinical benefits of D and T, in combination and as monotherapy, to treat adult a...